Bryostatin 1

Research use only, not for human use.

Bryostatin 1 (NSC 339555) is a macrocyclic lactone derived from a marine invertebrate, fuctions as an activator of PKC with high binding affinity (Ki=1.35 nM).

Bryostatin 1 (NSC 339555) is a macrocyclic lactone derived from a marine invertebrate, fuctions as an activator of PKC with high binding affinity (Ki=1.35 nM); functions like the phorbol esters biochemically in binding to and activating protein kinase C; inhibits tumor promotion by phorbol esters in SENCAR mouse skin, induces differentiation of B-chronic lymphocytic leukemia cells; blocks phorbol ester action in Friend cells, restores the differentiation respons with EC50 of 15 nM.Alzheimer Disease Phase 2 Clinical.

Bryostatin 1 (1 μM; 5 minutes; HT22 cells) treatment successfully recruits Munc13-1 from the cytosol to the plasma membrane. Effects of Bryostatin 1 on the other Munc13 family members, ubMunc13-2 and bMunc13-2, resembled those of Munc13-1 for translocation .The increased level of expression of Munc13-1 following a 24 h incubation with Bryostatin 1 in both HT22 and primary mouse hippocampal cells is observed.Bryostatin 1 can also affect the immune system by modulating dendritic cells (DCs) via toll-like receptor 4 (TLR4) through the MyD88-independent pathway, which favors an anti-inflammatory environment by inducing a type 2 phenotype that promotes the differentiation of CD4+ T-helper (Th) lymphocytes into Th2 versus Th1 effector cells. Western Blot Analysis Cell Line:HT22 cells Concentration:1 μM Incubation Time:5 minutes Result:Caused Munc13-1 to transfer to the membrane fraction.

Bryostatin 1 (30 μg/kg; intraperitoneal injection; 3 d per week; for 2 weeks; C57BL/6J mice) treatment abolishes the onset of EAE. Animal Model:Female C57BL/6J mice (8-12-week-old) with MOG35-55 Dosage:30 μg/kg Administration:Intraperitoneal injection; 3 d per week; for 2 weeks Result:Abolished the onset of experimental autoimmune encephalomyelitis (EAE).

NSC 339555 | Bryostatin1

Angiogenesis

PKC

PKC

Neurological Disease

——

83314-01-6

905.044

C47H68O17

>98% (HPLC)

——

CCC/C=C/C=C/C(O[C@@H](/C(C[C@@](O1)([H])C[C@H]([C@H](O)C)O2)=C/C(OC)=O)[C@]1(O)C(C)(C)/C=C/[C@@](O3)([H])C/C(C[C@@]3([H])C[C@@](O4)(O)C(C)(C)[C@@H](OC(C)=O)C[C@@]4([H])C[C@@H](O)CC2=O)=C\C(OC)=O)=O

2,4-Octadienoic acid, 25-(acetyloxy)-1,11,21-trihydroxy-17-(1-hydroxyethyl)-5,13-bis(2-methoxy-2-oxoethylidene)-10,10,26,26-tetramethyl-19-oxo-18,27,28,29-tetraoxatetracyclo[21.3.1.13,7.111,15]nonacos-8-en-12-yl ester, [1S-[1R*,3R*,5Z,7S*,8E,11R*,12R*(2E,

(-20℃)

With Ice Pack

≥ 2 years